{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:02:54Z","timestamp":1790143374537,"version":"4.0.1"},"reference-count":188,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016018","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T02:18:24Z","timestamp":1761790704000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tirzepatide for adults living with obesity"],"prefix":"10.1002","volume":"2025","author":[{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit, Institute of General Practice, Centre for Health and Society, Medical Faculty; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Guo","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit; Institute of General Practice, Centre for Health and Society, Medical Faculty, Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia B","family":"Varela","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Research Department; Universidad del Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakariya","family":"Aqra","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit; Institute of General Practice, Centre for Health and Society, Medical Faculty, Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Alhalahla","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit; Institute of General Practice, Centre for Health and Society, Medical Faculty, Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Medina Rodriguez","sequence":"additional","affiliation":[{"name":"Equipo de Seguridad Alimentaria; Distrito Especial de Medell\u00edn; Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison Leonardo","family":"Salvador Oscco","sequence":"additional","affiliation":[{"name":"Facultad de Medicina; Universidad Nacional de San Agust\u00edn de Arequipa; Arequipa Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernarda","family":"Pati\u00f1o Araujo","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Bari\u00e1trica Napole\u00f3n Salgado; Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Banda","sequence":"additional","affiliation":[{"name":"Evidence Informed Decision-Making Center, Department of Community and Environmental Health, School of Global and Public Health; Kamuzu University of Health Sciences; Lilongwe Malawi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Research Department; Universidad del Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bracchiglione","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Instituto de Salud Carlos III; Madrid Spain"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Meza","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-5549","authenticated-orcid":false,"given":"Eva","family":"Madrid","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"10.1002\/14651858.CD016018-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"e077310","DOI":"10.1136\/bmj-2023-077310","article-title":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","volume":"384","author":"Lane","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD016018-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.clnu.2024.04.016","article-title":"Ultra-processed foods and human health: an umbrella review and updated meta-analyses of observational evidence","volume":"43","author":"Dai","year":"2024","journal-title":"Clinical Nutrition"},{"issue":"2019","key":"10.1002\/14651858.CD016018-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD016018-BIB0004|cit4","unstructured":"World Health Organization Obesity and overweight www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"10.1002\/14651858.CD016018-BIB0005|cit5","unstructured":"Obesity and overweight WHO (World Health Organization) 2024 1 1 https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","article-title":"Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity","volume":"30","author":"Waldrop","year":"2024","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD016018-BIB0007|cit7","unstructured":"World Health Organization Obesity www.who.int\/news-room\/facts-in-pictures\/detail\/6-facts-on-obesity"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"19778","DOI":"10.1038\/s41598-020-75213-3","article-title":"The ongoing nutrition transition thwarts long-term targets for food security, public health and environmental protection","volume":"10","author":"Bodirsky","year":"2020","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1002\/14651858.CD016018-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/ijerph14040435","article-title":"Economic burden of obesity: a systematic literature review","volume":"14","author":"Tremmel","year":"2017","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhealeco.2011.10.003","article-title":"The medical care costs of obesity: an instrumental variables approach","volume":"31","author":"Cawley","year":"2012","journal-title":"Journal of Health Economics"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"w822","DOI":"10.1377\/hlthaff.28.5.w822","article-title":"Annual medical spending attributable to obesity: payer-and service-specific estimates","volume":"28","author":"Finkelstein","year":"2009","journal-title":"Health Affairs (Project Hope) (Millwood)"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/MED.0000000000000192","article-title":"Obesity medications: what does the future look like?","volume":"22","author":"Butsch","year":"2015","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"issue":"4","key":"10.1002\/14651858.CD016018-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD016018-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectrum"},{"key":"10.1002\/14651858.CD016018-BIB0015|cit15","unstructured":"US Food & Drug Administration - Assistance with FDA regulation www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209637Orig1s000TOC.cfm"},{"issue":"7","key":"10.1002\/14651858.CD016018-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"82\u20133","DOI":"10.1056\/NEJMe1506236","article-title":"Another agent for obesity - will this time be different?","volume":"373","author":"Siraj","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016018-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2741\/2785","article-title":"Dipeptidyl peptidase IV (DPP IV\/CD26) is a cell-surface plasminogen receptor","volume":"13","author":"Gonzalez-Gronow","year":"2008","journal-title":"Frontiers in Bioscience"},{"issue":"20","key":"10.1002\/14651858.CD016018-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4239\/wjd.v7.i20.572","article-title":"Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity","volume":"7","author":"Anandhakrishnan","year":"2016","journal-title":"World Journal of Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"Journal of Clinical Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD016018-BIB0023|cit23","first-page":"S2","article-title":"Defining success in obesity management","volume":"21","author":"R\u00f6ssner","year":"1997","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"issue":"8","key":"10.1002\/14651858.CD016018-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"International Journal of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD016018-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD016018-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD016018-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Therapy"},{"issue":"8","key":"10.1002\/14651858.CD016018-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-019-00812-7","article-title":"Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists","volume":"42","author":"Christensen","year":"2019","journal-title":"Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD016018-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","article-title":"An evaluation of liraglutide including its efficacy and safety for the treatment of obesity","volume":"21","author":"Lin","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3-4","key":"10.1002\/14651858.CD016018-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"202\u201330","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Review of Diabetic Studies"},{"issue":"9","key":"10.1002\/14651858.CD016018-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs - FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"217\u201332","DOI":"10.1586\/17446651.2015.1057502","article-title":"A systematic review of the safety of incretin-based therapies in type 2 diabetes","volume":"11","author":"Evans","year":"2016","journal-title":"Expert Review of Endocrinology & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD016018-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"906\u20138","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Current Obesity Reports"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204.pub2","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD016018-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006423.pub2","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD016018-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s11096-024-01779-x","article-title":"Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2024","journal-title":"International Journal of Clinical Pharmacy"},{"key":"10.1002\/14651858.CD016018-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1277113","DOI":"10.3389\/fpubh.2024.1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai","year":"2024","journal-title":"Frontiers in Public Health"},{"key":"10.1002\/14651858.CD016018-BIB0040|cit40","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Standards for the conduct of new Cochrane Intervention Reviews. In: Higgins JP, Lasserson T, Thomas J, Flemyng E, Churchill R. Methodological Expectations of Cochrane Intervention Reviews Cochrane: London"},{"issue":"71","key":"10.1002\/14651858.CD016018-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD016018-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015092","article-title":"Glucagon-like peptide-1 analogues for overweight or obese adults","author":"Madrid","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD016018-BIB0043|cit43","unstructured":"Madrid E Franco J Meza N Bracchiglione J Ocara M Escobar-Liquitay C Glucagon-like peptide-1 (GLP-1) analogues for adult people with obesity: protocol for asystematic review with meta-analysis. PROSPERO 2025 CRD420250654193 Available from https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420250654193"},{"issue":"9","key":"10.1002\/14651858.CD016018-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","article-title":"Incretin-based therapies for the treatment of obesity-related diseases","volume":"2","author":"Caruso","year":"2024","journal-title":"NPJ Metabolic Health and Disease"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.clinme.2025.100298","article-title":"GLP-1 receptor agonist therapy and pregnancy: evolving and emerging evidence","volume":"25","author":"Varughese","year":"2025","journal-title":"Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Annals of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016018-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: a systematic review of the literature","volume":"84","author":"Topp","year":"2015","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"6","key":"10.1002\/14651858.CD016018-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"179\u201386","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"Journal of Public Health"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1111\/obr.12961","article-title":"Core outcome set for behavioural weight management interventions for adults with overweight and obesity: standardised reporting of lifestyle weight management interventions to aid evaluation (STAR-LITE)","volume":"21","author":"Mackenzie","year":"2020","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD016018-BIB0052|cit52","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies [last updated September 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-04-technical-supplement-searching-and-selecting-studies"},{"key":"10.1002\/14651858.CD016018-BIB0053|cit53","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD016018-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016018-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"j2998","DOI":"10.1136\/bmj.j2998","article-title":"Enhancing the usability of systematic reviews by improving the consideration and description of interventions","volume":"358","author":"Hoffmann","year":"2017","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016018-BIB0056|cit56","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies (last updated August 2022). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-07"},{"key":"10.1002\/14651858.CD016018-BIB0057|cit57","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD016018-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016018-BIB0059|cit59","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-06"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"7644","key":"10.1002\/14651858.CD016018-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016018-BIB0062|cit62","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10"},{"key":"10.1002\/14651858.CD016018-BIB0063|cit63","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-12"},{"key":"10.1002\/14651858.CD016018-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7382","key":"10.1002\/14651858.CD016018-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016018-BIB0066|cit66","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016018-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD016018-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-00548","article-title":"GRADE certainty ratings: thresholds rather than categories of contextualization (GRADE guidance 41)","volume":"2025","author":"Hultcrantz","year":"2025","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD016018-BIB0069|cit69","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-14"},{"key":"10.1002\/14651858.CD016018-BIB0070|cit70","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016018-BIB0071|cit71","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","article-title":"Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments","volume":"74","author":"Santesso","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD016018-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD016018-BIB0076|cit76","unstructured":"A study of tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction (HFpEF) and obesity: the SUMMIT trial https:\/\/clinicaltrials.gov\/study\/NCT04847557"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, a preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"544\u201351","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.eprac.2024.03.253","article-title":"#1696673 Weight reduction over time in tirzepatide-treated participants by early weight loss response - post hoc analysis in SURMOUNT-1","volume":"30","author":"Gudzune","year":"2024","journal-title":"Endocrine Practice"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD016018-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db23-71-LB","article-title":"Tirzepatide reduces the predicted risk of developing type 2 Diabetes-SURMOUNT-1 post hoc analysis by prediabetes status","volume":"72","author":"Hankosky","year":"2023","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016018-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000538577","article-title":"Evaluation of the incidence of gallbladder and biliary diseases with TZP across body weight reduction categories in the SURMOUNT program","volume":"17","author":"Jacobi","year":"2024","journal-title":"Obesity Facts"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/oby.23625","article-title":"Tirzepatide-induced weight loss Is associated with body composition improvements across age groups","volume":"30","author":"Kushner","year":"2022","journal-title":"Obesity"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000538577","article-title":"Tirzepatide for the treatment of obesity reduced body weight across body mass index categories: post hoc analysis of the SURMOUNT 1-4 trials","volume":"17","author":"Le Roux","year":"2024","journal-title":"Obesity Facts"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000530456","article-title":"Time to weight plateau with tirzepatide across BMI categories in SURMOUNT-1","volume":"16","author":"Batterham","year":"2023","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016018-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db23-70-LB","article-title":"Tirzepatide reduces the predicted risk of developing type 2 diabetes: post hoc analysis of the SURMOUNT-1 trial","volume":"72","author":"Hankosky","year":"2023","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD016018-BIB0089|cit89","unstructured":"Machineni S Yu M Dunn J Stefanski A Wang F Bunck M Effect of tirzepatide on body weight reduction by number of obesity-related complications Obesity 2022 50 10.1002\/oby.23625"},{"issue":"7","key":"10.1002\/14651858.CD016018-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.jcjd.2023.10.258","article-title":"Tolerability and weight reduction of tirzepatide in adults with obesity or overweight","volume":"47","author":"Rubino","year":"2023","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD016018-BIB0091|cit91","unstructured":"Poon JL Zhang S Ford J Malik R Stefanski A Evaluating health-related quality of life with tirzepatide in the SURMOUNT-1 study Obesity 2022 50 10.1002\/oby.23625"},{"key":"10.1002\/14651858.CD016018-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/circ.146.suppl_1.10370","article-title":"Effects of tirzepatide on 24-hour ambulatory blood pressure and heart rate in adults with obesity: results from the SURMOUNT-1 ambulatory blood pressure monitoring sub-study","volume":"146 Suppl 1","author":"De Lemos","year":"2022","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD016018-BIB0093|cit93","unstructured":"Efficacy and safety of tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight with weight- related comorbidities: a randomized, double-blind, placebo-controlled trial (SURMOUNT-1) https:\/\/clinicaltrials.gov\/study\/NCT04184622 2019"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"A6-A7","DOI":"10.1210\/jendso\/bvad114.011","article-title":"Improved mental and psychosocial patient-reported outcomes among people with obesity treated with tirzepatide: results From SURMOUNT-1 study","volume":"7","author":"Poon","year":"2023","journal-title":"Jurnal of the Endocrine Society"},{"key":"10.1002\/14651858.CD016018-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"S44-5","DOI":"10.1055\/s-0043-1767938","article-title":"Tirzepatide reduces body weight across body mass index (BMI) categories: a SURMOUNT-1 prespecified analysis","volume":"18","author":"Aronne","year":"2023","journal-title":"Diabetologie und Stoffwechsel"},{"key":"10.1002\/14651858.CD016018-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"53-4","DOI":"10.1159\/000530456","article-title":"Tirzepatide for the treatment of obesity: the SURMOUNT-1 clinical trial","volume":"16","author":"Aronne","year":"2023","journal-title":"Obesity Facts"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"554-5","DOI":"10.1159\/000538577","article-title":"Body weight reduction in women treated with tirzepatide by menopausal stage: a post hoc analysis from the SURMOUNT program","volume":"17","author":"Ciudin","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD016018-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"408-9","DOI":"10.1159\/000538577","article-title":"Early weight loss and reported gastrointestinal adverse events in tirzepatide-treated participants in the SURMOUNT 1-2 trials","volume":"17","author":"Kokkinos","year":"2024","journal-title":"Obesity Facts"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"S8-9","DOI":"10.1016\/j.orcp.2024.09.020","article-title":"Body weight reduction in women treated with tirzepatide by menopausal stage: a post hoc analysis from the SURMOUNT program","volume":"18","author":"Mihai","year":"2024","journal-title":"Obesity Research & Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"S35-6","DOI":"10.1016\/j.eprac.2023.03.084","article-title":"Abstract #1395974: achieving waist circumference targets with once weekly tirzepatide for the treatment of obesity","volume":"29","author":"Neeland","year":"2023","journal-title":"Endocrine Practice"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"S166-7","DOI":"10.1016\/j.cjca.2023.06.401","article-title":"Tolerability and weight reduction of tirzepatide in adults with obesity or overweight","volume":"39","author":"Rubino","year":"2023","journal-title":"Canadian Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"S68-S69","DOI":"10.1159\/000538577","article-title":"#1701797 Waist-to-height ratio shifts over time in tirzepatide-treated participants - post hoc analysis in SURMOUNT-1 and SURMOUNT-2","volume":"30","author":"Tchang","year":"2024","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD016018-BIB0103|cit103","unstructured":"Srinath R Pedersen S Neff L Cao D Kao CY Stefanski A SAT660 predictors of achieving body weight reduction \u226520% with tirzepatide in people with overweight or obesity in SURMOUNT-1 Journal of the Endocrine Society bvad114.108 10.1210\/jendso\/bvad114.108"},{"issue":"4","key":"10.1002\/14651858.CD016018-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"E41-3","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u2265 27 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"De Lemos","year":"2024","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD016018-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000530456","article-title":"The tirzepatide clinical development program: rationale and design of the SURMOUNT trials","volume":"16","author":"Le Roux","year":"2023","journal-title":"Obesity"},{"issue":"12","key":"10.1002\/14651858.CD016018-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1111\/dom.15269","article-title":"Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: post hoc analysis of the SURMOUNT-1 trial","volume":"25","author":"Hankosky","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"S69-70","DOI":"10.1016\/j.eprac.2024.03.261","article-title":"#1704142 Evaluating the association between early body weight changes with tirzepatide and categorical weight reduction in people with obesity or overweight: a post-hoc analysis","volume":"30","author":"Addison","year":"2024","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD016018-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1681\/ASN.20233411S141b","article-title":"Effect of tirzepatide on kidney function in people with excess body weight: a post hoc analysis of the SURMOUNT-1 trial","volume":"34","author":"Heerspink","year":"2023","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.eprac.2024.03.262","article-title":"#1704946 Improvements in physical functioning among participants with obesity with limitations in physical function at baseline: results from SURMOUNT-1 and SURMOUNT-2 trials","volume":"30","author":"Hunter","year":"2024","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD016018-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"74-5","DOI":"10.1159\/000538577","article-title":"Tirzepatide reduced body weight and waist circumference in people with overweight or obesity regardless of disease duration: post hoc analysis of the SURMOUNT 1-4 trials","volume":"17","author":"Muscogiuri","year":"2024","journal-title":"Obesity Facts"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program","volume":"31","author":"Le Roux","year":"2023","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD016018-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"A264-5","DOI":"10.1093\/sleep\/zsae067.0620","article-title":"Effect of tirzepatide on weight loss in patients with obstructive sleep apnea and obesity from SURMOUNT-1","volume":"47 Suppl 1","author":"Grunstein","year":"2024","journal-title":"Sleep"},{"issue":"19","key":"10.1002\/14651858.CD016018-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"key":"10.1002\/14651858.CD016018-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1055\/s-0043-1767938","article-title":"Tirzepatide reduces body weight across BMI categories: a SURMOUNT-1 pre-specified analysis","volume":"18","author":"Aronne","year":"2022","journal-title":"Diabetologie und Stoffwechsel"},{"issue":"10402","key":"10.1002\/14651858.CD016018-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"S34-5","DOI":"10.1016\/j.orcp.2024.09.080","article-title":"Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2","volume":"18","author":"Sattar","year":"2024","journal-title":"Obesity Research & Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.eprac.2024.03.263","article-title":"#1704957 Tirzepatide improves health-related quality of life in participants with obesity or overweight and type 2 diabetes: results from phase 3 SURMOUNT-2 trial","volume":"30","author":"Hunter","year":"2024","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD016018-BIB0118|cit118","unstructured":"A study of tirzepatide (LY3298176) in participants with type 2 diabetes who have obesity or are overweight (SURMOUNT-2) https:\/\/clinicaltrials.gov\/study\/NCT04657003"},{"issue":"11","key":"10.1002\/14651858.CD016018-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD016018-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"S83-4","DOI":"10.1055\/s-0044-1785401","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3)","volume":"19","author":"Wadden","year":"2024","journal-title":"Diabetologie und Stoffwechsel"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.eprac.2024.03.260","article-title":"#1702836 Tirzepatide improved health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-3 phase 3 trial","volume":"30","author":"Hunter","year":"2024","journal-title":"Endocrine Practice"},{"issue":"6","key":"10.1002\/14651858.CD016018-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/s41591-023-02597-w","article-title":"Author correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"30","author":"Wadden","year":"2024","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD016018-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"A29","DOI":"10.1210\/jendso\/bvae163.053","article-title":"Weight reduction is associated with improved quality of life in patients in SURMOUNT-3","volume":"8 Suppl 1","author":"Gibble","year":"2024","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD016018-BIB0124|cit124","unstructured":"A study of tirzepatide (LY3298176) in participants after a lifestyle weight loss program (SURMOUNT-3) https:\/\/clinicaltrials.gov\/study\/NCT04657016 2020"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD016018-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1210\/jendso\/bvae163.043","article-title":"Tirzepatide improved mental and psychosocial health-related quality of life in adults with obesity or overweight: results from the SURMOUNT-4 phase 3 trial","volume":"8 Suppl 1","author":"Gibble","year":"2024","journal-title":"Journal of the Endocrine Society"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.orcp.2024.09.079","article-title":"Patient experiences with tirzepatide in SURMOUNT-4","volume":"18","author":"Jouravskaya","year":"2024","journal-title":"Obesity Research & Clinical Practice"},{"key":"10.1002\/14651858.CD016018-BIB0128|cit128","unstructured":"A study of tirzepatide (LY3298176) in participants with obesity or overweight for the maintenance of weight loss https:\/\/clinicaltrials.gov\/study\/NCT04660643 2020"},{"key":"10.1002\/14651858.CD016018-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"A23","DOI":"10.1210\/jendso\/bvae163.042","article-title":"Tirzepatide improved health-related quality of life in people with obesity or overweight: results from SURMOUNT-4 phase 3 trial","volume":"8 Suppl 1","author":"Gibble","year":"2024","journal-title":"Journal of the Endocrine Society"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.eprac.2024.03.264","article-title":"#1706263 Qualitative insights on meaningful change in physical functioning in SURMOUNT-4 participants","volume":"30","author":"Collins","year":"2024","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD016018-BIB0131|cit131","unstructured":"A study of tirzepatide (LY3298176) in participants with obesity or overweight with weight related comorbidities (SURMOUNT-5) https:\/\/clinicaltrials.gov\/study\/NCT05822830"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD016018-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD016018-BIB0134|cit134","unstructured":"Erratum: tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial (JAMA (2024) DOI: 10.1001\/jama.2024.9217) JAMA 2024 10.1001\/jama.2024.12249"},{"key":"10.1002\/14651858.CD016018-BIB0135|cit135","unstructured":"A study of tirzepatide (LY3298176) in Chinese participants without type 2 diabetes who have obesity or overweight (SURMOUNT-CN) https:\/\/clinicaltrials.gov\/study\/NCT05024032 2021"},{"key":"10.1002\/14651858.CD016018-BIB0136|cit136","unstructured":"Zhao L Cheng Z Lu Y Liu M Chen H Zhang M Efficacy and safety of tirzepatide once weekly in Chinese participants with obesity or with overweight and weight-related comorbidities 59th EASD Annual Meeting 2023 S274-5 10.1007\/s00125-023-05969-6"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"13","author":"Kadowaki","year":"2025","journal-title":"Lancet. Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD016018-BIB0138|cit138","unstructured":"A study of tirzepatide (LY3298176) in participants with obesity disease (SURMOUNT-J) https:\/\/clinicaltrials.gov\/study\/NCT04844918 2021"},{"issue":"13","key":"10.1002\/14651858.CD016018-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016018-BIB0140|cit140","unstructured":"Obstructive sleep apnea master protocol GPIF: a study of tirzepatide (LY3298176) in participants with obstructive sleep apnea (SURMOUNT-OSA) https:\/\/clinicaltrials.gov\/study\/NCT05412004 2022"},{"key":"10.1002\/14651858.CD016018-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"A6565EP","DOI":"10.1016\/j.chest.2024.07.189","article-title":"Tirzepatide reduced sleep apnea-specific hypoxic burden in participants with obstructive sleep apnea and obesity (SURMOUNT-OSA)","volume":"166 Suppl 4","author":"Azarbarzin","year":"2024","journal-title":"Chest"},{"key":"10.1002\/14651858.CD016018-BIB0142|cit142","unstructured":"A study in patients with obesity and obstructive sleep apnea https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-004552-41\/CZ 2022"},{"issue":"101242342","key":"10.1002\/14651858.CD016018-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"107516","DOI":"10.1016\/j.cct.2024.107516","article-title":"Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial","volume":"141","author":"Malhotra","year":"2024","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD016018-BIB0144|cit144","unstructured":"The effectiveness and sustainability of health outcomes from an advanced digital weight-loss programme in the UK https:\/\/www.isrctn.com\/ISRCTN14812004"},{"issue":"11","key":"10.1002\/14651858.CD016018-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/dom.15903","article-title":"The effectiveness and sustainability of health outcomes from a holistic digital weight-loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK","volume":"26","author":"Talay","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD016018-BIB0146|cit146","unstructured":"A study of LY3841136 in Japanese participants with obesity or overweight https:\/\/clinicaltrials.gov\/study\/NCT06297616"},{"key":"10.1002\/14651858.CD016018-BIB0147|cit147","unstructured":"Eli L A study of LY3841136 in Japanese participants with obesity or overweight https:\/\/trials.lilly.com\/en-US\/trial\/466940"},{"key":"10.1002\/14651858.CD016018-BIB0148|cit148","unstructured":"A research study comparing how well different doses of the medicine NN0519-0130 help people with excess body weight lose weight https:\/\/clinicaltrials.gov\/study\/NCT06326060"},{"key":"10.1002\/14651858.CD016018-BIB0149|cit149","unstructured":"A research study comparing how well different doses of the medicine NNC0519-0130 help people with excess body weight lose weight (NN9541-5015) https:\/\/jrct.niph.go.jp\/latest-detail\/jRCT2051230198"},{"key":"10.1002\/14651858.CD016018-BIB0150|cit150","unstructured":"A randomized controlled trial comparing the effectiveness of different treatment options for weight management after discontinuation of semaglutide and tirzepatide (GLP1 transition trial) https:\/\/clinicaltrials.gov\/study\/NCT06605703"},{"key":"10.1002\/14651858.CD016018-BIB0151|cit151","unstructured":"A study of tirzepatide (LY3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD) https:\/\/clinicaltrials.gov\/study\/NCT05536804"},{"key":"10.1002\/14651858.CD016018-BIB0152|cit152","unstructured":"Eli L Tirzepatide mechanism of action study on renal function (TREASURE-CKD) https:\/\/trials.lilly.com\/en-US\/trial\/360461"},{"key":"10.1002\/14651858.CD016018-BIB0153|cit153","unstructured":"Tirzepatide study of renal function in people with overweight or obesity and chronic kidney disease with or without type 2 diabetes: focus on kidney hypoxia in relation to fatty kidney disease using multiparametric magnetic resonance imaging https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-005273-47\/DK"},{"key":"10.1002\/14651858.CD016018-BIB0154|cit154","unstructured":"Tirzepatide study of renal function in people with overweight or obesity and chronic kidney disease with or without type 2 diabetes: focus on kidney hypoxia in relation to fatty kidney disease using multiparametric magnetic resonance imaging (TREASURE-CK) https:\/\/onderzoekmetmensen.nl\/en\/trial\/51386"},{"key":"10.1002\/14651858.CD016018-BIB0155|cit155","unstructured":"A study of investigational tirzepatide (LY3298176) doses in participants with type 2 diabetes and obesity https:\/\/clinicaltrials.gov\/study\/NCT06037252"},{"key":"10.1002\/14651858.CD016018-BIB0156|cit156","unstructured":"Eli L A study of investigational tirzepatide (LY3298176) doses in participants with type 2 diabetes and obesity https:\/\/trials.lilly.com\/en-US\/trial\/422915"},{"key":"10.1002\/14651858.CD016018-BIB0157|cit157","unstructured":"A master protocol for a randomized, controlled, clinical trial of multiple interventions for chronic weight management in adult participants with obesity or overweight https:\/\/clinicaltrials.gov\/study\/NCT06143956"},{"key":"10.1002\/14651858.CD016018-BIB0158|cit158","unstructured":"Ixekizumab concomitantly administered with tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight (TOGETHER-pso) https:\/\/clinicaltrials.gov\/study\/NCT06588283"},{"key":"10.1002\/14651858.CD016018-BIB0159|cit159","unstructured":"Efficacy and safety of ixekizumab or ixekizumab concomitantly administered with tirzepatide in adult participants with active psoriatic arthritis and obesity or overweight: a phase 3b, randomized, multicenter, open-label study (TOGETHER-psa) https:\/\/clinicaltrials.gov\/study\/NCT06588296"},{"key":"10.1002\/14651858.CD016018-BIB0160|cit160","unstructured":"Eli L Ixekizumab concomitantly administered with tirzepatide in adults with psoriatic arthritis and obesity or overweight https:\/\/trials.lilly.com\/en-US\/trial\/533080"},{"key":"10.1002\/14651858.CD016018-BIB0161|cit161","unstructured":"A study to investigate weight management with LY3841136 and tirzepatide (LY3298176), alone or in combination, in adult participants with obesity or overweight with type 2 diabetes https:\/\/clinicaltrials.gov\/study\/NCT06603571"},{"key":"10.1002\/14651858.CD016018-BIB0162|cit162","unstructured":"Eli L A study to investigate weight management with LY3841136 and tirzepatide (LY3298176), alone or in combination, in adult participants with obesity or overweight with type 2 diabetes https:\/\/trials.lilly.com\/en-US\/trial\/533180"},{"key":"10.1002\/14651858.CD016018-BIB0163|cit163","unstructured":"Efficacy and safety of gzr18 injected every 2 weeks (Q2W) in participants without type 2 diabetes, who have obesity or are overweight: a randomized, tirzepatide- and placebo-controlled study https:\/\/clinicaltrials.gov\/study\/NCT06737042"},{"key":"10.1002\/14651858.CD016018-BIB0164|cit164","unstructured":"A study of LY3298176 (tirzepatide) for the maintenance of body weight reduction in participants who have obesity or overweight with weight-related comorbidities https:\/\/clinicaltrials.gov\/study\/NCT06047548"},{"key":"10.1002\/14651858.CD016018-BIB0165|cit165","unstructured":"Eli L A study to investigate weight management with bimagrumab (LY3985863) and tirzepatide (LY3298176), alone or in combination, in adults with obesity or overweight https:\/\/trials.lilly.com\/en-US\/trial\/546217"},{"key":"10.1002\/14651858.CD016018-BIB0166|cit166","unstructured":"A study to investigate weight management with bimagrumab (LY3985863) and tirzepatide (LY3298176), alone or in combination, in adults with obesity or overweight https:\/\/clinicaltrials.gov\/study\/NCT06643728"},{"key":"10.1002\/14651858.CD016018-BIB0167|cit167","unstructured":"A study of tirzepatide (LY3298176) on the reduction on morbidity and mortality in adults with obesity (SURMOUNT-MMO) https:\/\/clinicaltrials.gov\/study\/NCT05556512"},{"key":"10.1002\/14651858.CD016018-BIB0168|cit168","unstructured":"The effects of tirzepatide in people with overweight\/obesity and coronary artery disease https:\/\/clinicaltrials.gov\/study\/NCT06606821"},{"key":"10.1002\/14651858.CD016018-BIB0169|cit169","unstructured":"The effects of tirzepatide in people with overweight\/obesity and coronary artery disease https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2023-505270-15-00"},{"key":"10.1002\/14651858.CD016018-BIB0170|cit170","unstructured":"Investigating and optimising physical function with weight loss https:\/\/www.isrctn.com\/ISRCTN10203365"},{"key":"10.1002\/14651858.CD016018-BIB0171|cit171","unstructured":"Effect of subcutaneous tirzepatide once-weekly in patients with obesity and knee osteoarthritis (STOP KNEE-OA): a randomized, double-blind, placebo-controlled trial https:\/\/clinicaltrials.gov\/study\/NCT06191848"},{"key":"10.1002\/14651858.CD016018-BIB0172|cit172","unstructured":"The combination of tirzepatide and resistance exercise (T-REX) for the management of body composition https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=385806"},{"key":"10.1002\/14651858.CD016018-BIB0173|cit173","unstructured":"The effect of substantial weight loss with tirzepatide on heart failure with preserved ejection fraction in people with obesity https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=387334"},{"key":"10.1002\/14651858.CD016018-BIB0174|cit174","unstructured":"Effect of tirzepatide on asthma control in obese asthmatics https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12624001278527"},{"key":"10.1002\/14651858.CD016018-BIB0175|cit175","unstructured":"Safety and Efficacy of Tirzepatide \u00b1 Exercise in adults with Obesity and Type 1 Diabetes Mellitus: a pilot 3-arm open-label randomised controlled trial (TEX OB-1) https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12624001369516"},{"key":"10.1002\/14651858.CD016018-BIB0176|cit176","unstructured":"Tirzepatide for the treatment of concurrent type 1 diabetes and overweight or obesity (TZP-T1D) https:\/\/clinicaltrials.gov\/study\/NCT06180616"},{"issue":"5","key":"10.1002\/14651858.CD016018-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/bmjebm-2019-111230","article-title":"What to do with a clinical trial with conflicts of interest","volume":"25","author":"Lundh","year":"2019","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"7","key":"10.1002\/14651858.CD016018-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012990.pub2","article-title":"GLP-1 receptor agonists for Parkinson's disease","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD016018-BIB0179|cit179","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015849.pub2","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes","author":"Natale","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD016018-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013650.pub2","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","author":"Kanie","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD016018-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"CD009966","DOI":"10.1002\/14651858.CD009966.pub3","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD016018-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"1230206","DOI":"10.3389\/fendo.2023.1230206","article-title":"The effects of subcutaneous tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials","volume":"14","author":"Rohani","year":"2023","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"issue":"12","key":"10.1002\/14651858.CD016018-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD016018-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"348","DOI":"10.7570\/jomes24008","article-title":"The effects of tirzepatide on lipid profile: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Mahar","year":"2024","journal-title":"Journal of Obesity & Metabolic Syndrome"},{"key":"10.1002\/14651858.CD016018-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"e13929","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"1","author":"Berg","year":"2025","journal-title":"Obesity Reviews"},{"issue":"1","key":"10.1002\/14651858.CD016018-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD016018-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.eclinm.2024.102661","article-title":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study","volume":"73","author":"Moll","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:19:00Z","timestamp":1790140740000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016018"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":188,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016018","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}